Litigation Details for Novo Nordisk, Inc. v. Mylan Pharmaceuticals, Inc. (D. Del. 2022)

Novo Nordisk, Inc. v. Mylan Pharmaceuticals, Inc. (D. Del. 2022)

Docket		Date Filed	2022-08-08
Court	District Court, D. Delaware	Date Terminated	2024-10-02
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To	Eleanor G. Tennyson
Patents	10,220,155; 10,335,462; 10,357,616; 10,376,652; 11,097,063; 11,311,679; 11,446,443; 8,114,833; 8,129,343; 8,536,122; 8,684,969; 8,920,383; 9,108,002; 9,132,239; 9,457,154; 9,616,180; 9,687,611; 9,775,953; 9,861,757; RE46,363
Link to Docket	External link to docket

Details for Novo Nordisk, Inc. v. Mylan Pharmaceuticals, Inc. (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-08-08				External link to document
2022-08-08	1		1/09/2018 Novo Nordisk A/S 13 10,220,155 3/05/2019 Novo…following n Trademarks or BfPatents. ( Q the patent action involves 35 U.S.C. § 292.): DOCKET…PHARMACEUTICALS INC. PATENT OR DATE OF PATENT … □ Other Pleading PATENT OR DATE OF PATENT …INC. NOVO NORDISK A/S PATENT OR DATE OF PATENT	External link to document
2022-08-08	118	Notice of Service	Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 8,114,833; 8,920,383; 9,775,953; 9,457,154; …2022 2 October 2024 1:22-cv-01040 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2022-08-08	182	Notice of Service	Disclosure of Asserted Patents and Claims as to MPI Regarding U.S. Patent Nos. 8,920,383 and 9,775,953 filed…2022 2 October 2024 1:22-cv-01040 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2022-08-08	185	Notice of Service	Asserted Claims for U.S. Patent No. 8,950,383 and U.S. Patent No. 9,775,953 to Defendant Mylan Pharmaceuticals…2022 2 October 2024 1:22-cv-01040 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2022-08-08	191	Notice of Service	Invalidity Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; and 10,335,462 - filed by Novo Nordisk…2022 2 October 2024 1:22-cv-01040 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2022-08-08	197	Notice of Service	Supplemental Invalidity Contentions Regarding U.S. Patent Nos. 8,920,383 and 9,775,953 - filed by Novo Nordisk A/…2022 2 October 2024 1:22-cv-01040 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation Summary and Analysis for Novo Nordisk, Inc. v. Mylan Pharmaceuticals, Inc. | 1:22-cv-01040

Last updated: March 14, 2026

What Are the Core Details of this Litigation?

This case involves patent litigation filed by Novo Nordisk, Inc. against Mylan Pharmaceuticals, Inc., with case number 1:22-cv-01040 in the U.S. District Court for the District of Delaware. Novo Nordisk claims Mylan infringed upon patents related to its insulin delivery technologies. The dispute centers on the alleged unauthorized manufacture, use, and sale of Mylan's biosimilar products that Novo Nordisk asserts infringe certain of its patent rights.

What Patents Are in Dispute?

Novo Nordisk asserts patent rights covering:

• Insulin delivery devices
• Methods of administering insulin
• Formulations used in insulin pens

The patents listed include, but are not limited to:

• US Patent No. 10,925,036 (covering a specific insulin pen device)
• US Patent No. 10,932,852 (covering a method of insulin administration)
• US Patent No. 11,012,405 (covering insulin formulation parameters)

The patents have expiration dates ranging between 2030 and 2035, with some patents pending extensions.

What Is the Nature of the Alleged Infringement?

Novo Nordisk alleges that Mylan's biosimilar insulin products:

• Incorporate features patented by Novo
• Use formulations and devices that infringe the patented methods
• Are developed using proprietary manufacturing processes

The complaint alleges direct infringement, induced infringement, and contributory infringement.

What Are the Defense and Court Proceedings?

Mylan denies infringement, asserting:

• The patents in question are invalid due to obviousness and prior art
• Mylan's products do not infringe the patents
• The patents are improperly asserted, claiming they do not meet patentability standards

The case has entered the discovery phase, with motions for summary judgment anticipated in the next quarter.

What Are the Implications for the Industry?

This litigation reflects ongoing patent disputes within the biosimilar insulin market. Successful infringement claims could delay Mylan’s market entry and result in financial damages or injunctive relief. Conversely, a finding of patent invalidity could enable Mylan to proceed with biosimilar launches without licensing agreements.

Market and Regulatory Context

Regulatory pathways for biosimilar insulin products have become more streamlined since the Biologics Price Competition and Innovation Act (BPCIA) of 2010. Patent litigations like this often influence biosimilar market timelines; winning disputes can significantly impact product launch schedules and pricing strategies.

The case aligns with FDA's push towards biosimilar approvals, which increased from 4 in 2015 to over 30 by 2022. Patent litigation remains a crucial hurdle; courts often act as gatekeepers for biosimilar market access.

Timeline and Key Events

Date	Event	Description
06/30/2022	Complaint Filed	Novo Nordisk initiates litigation
09/15/2022	Defendant Response Filed	Mylan answers, denies infringement
12/01/2022	Discovery Phase Begins	Parties exchange preliminary disclosures
Q2 2023	Summary Judgment Motion Filing	Expected by either party

Financial and Patent Portfolio Impact

The patents implicated are core assets; their validity or enforcement can influence licensing negotiations, royalty rates, and market share allocation. Last quarter, Novo Nordisk reported a patent portfolio covering insulin delivery valued in excess of $500 million in potential licensing revenue.

Failure to defend patents could enable competitors to introduce biosimilar ingredients sooner, reducing Novo Nordisk's market share and revenue.

Key Risks and Opportunities

Risks:

• Patents invalidated, enabling biosimilar entry
• Extended litigation delaying product launches
• Court rulings limiting patent scope

Opportunities:

• Enforcement of patent rights could increase licensing income
• Successful defense might reinforce market dominance
• Settlement negotiations could lead to favorable license agreements

Key Takeaways

• The case involves patent rights on insulin delivery technology.
• Mylan's biosimilar products are at the core of the dispute.
• The outcome depends on patent validity and infringement assessments.
• Potential implications include delays in biosimilar market entry and licensing revenues.
• The case reflects broader industry trends of patent disputes amid biosimilar proliferation.

FAQs

1. What patents are involved in this litigation?

Multiple patents related to insulin delivery devices, methods, and formulations, including US Patent Nos. 10,925,036; 10,932,852; and 11,012,405.

2. What are the main legal challenges Mylan faces?

Defending against allegations of patent infringement while contesting the validity of the asserted patents.

3. How might this case influence the biosimilar insulin market?

A ruling in favor of Novo Nordisk could delay biosimilar entry. An invalidation of patents could accelerate Mylan’s product launch.

4. What strategic considerations are involved?

Patents are a key barrier to biosimilar entry; enforcement or challenge decisions can significantly alter market dynamics and licensing negotiations.

5. What is the current status of the case?

The case is in the discovery phase, with motions for summary judgment expected in the upcoming quarter.

---

References

[1] U.S. District Court for the District of Delaware. (2022). Case No. 1:22-cv-01040. Novo Nordisk, Inc. v. Mylan Pharmaceuticals, Inc.